Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial

Annals of Internal Medicine

Volumn 120, Issue 10, 1994, Pages 834-844

  De Pauw, Ben E ^a   Deresinski, Stanley C ^b   Feld, Ronald ^c   Lane Allman, Elizabeth F ^d   Donnelly, J Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CEFTAZIDIME; COTRIMOXAZOLE; ERYTHROMYCIN; PIPERACILLIN; SULFAMETHOXAZOLE; TOBRAMYCIN; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ACUTE LEUKEMIA; ADULT; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MIXTURE; FEMALE; FEVER; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEGIONNAIRE DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUPERINFECTION;

EID: 0028346573     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-120-10-199405150-00004     Document Type: Article

References (36)

1. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987;317:1692-8.
2. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-5.
3. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. Combination of amikacin and carbenicillin with or without cephazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol. 1983;1:597-603.
4. Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH. Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1981;71:983-90.
5. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984;144:1766-70.
6. Middleman EL, Watanabe A, Kaizer H, Bodey GP. Antibiotic combinations for infections in neutropenic patients: evaluation of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972;30: 573-9.
7. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984;26: 870-5.
8. Bodey GP, Feld R, Burgess MA. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. Am J Med Sci. 1976;271:179-86.
9. De Pauw BE, Kauw F, Muytjens H, Williams KJ, Bothof T. Randomized study of Ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother. 1983;12:93-9.
10. Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983;12:101-10.
11. Ramphal R, Kramer BS, Rand KH, Weiner RS, Shands JAV Jr. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother. 1983;12(Suppl A): 81-8.
12. De Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1985;28:824-8.
13. Donnelly JP, Worsley AM, Marcus RE, Goldman JM, Cohen J, Worsley AM, et al. Ceftazidime as first-line therapy for the treatment of fever in acute leukaemia. J Infect. 1985;11:205-15.
14. Verhagen CS, De Pauw B, de Witte T, Janssen J, Williams K, De Mulder P, et al. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1987;31:191-6.
15. Nováková I, Donnelly J, De Pauw B. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis. 1990;22:705-11.
16. Granowetter L, Wells H, Lange BJ. Ceftazidime with and without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient. Pediatr J Infect Dis. 1988;7:165-70.
17. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552-8.
18. Young LS. Empirical antimicrobial therapy in the neutropenic host [Editorial]. N Engl J Med. 1986;315:580-1.
19. Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother. 1992;36:1062-7.
20. Elliott CR, Pater JL. The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clin Invest Med. 1988;11:327-30.
21. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627-32.
22. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119:584-93.
23. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381-96.
24. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with and without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992;152:283-91.
25. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115:849-59
26. Bodey GP, Fainstein V, Elling LS, Anaissie E, Roslon K, Khardori N, et al. Beta-lactam regimens for the febrile neutropenic patient Cancer. 1990;65:9-16.
27. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24(Suppl 1):S35-45.
28. Wade JC. Antibiotic therapy for the febrile granulocytic cancer patient: combination therapy vs. monotherapy. J Infect Dis. 1989; 11(Suppl 7):S1572-81.
29. Feld R, Louie TJ, Mandell L, Bow EJ, Robson HG, Chow A, et al. A multicenter comparative trial of tobramycin and ticaricillin vs moxalactam and ticaricillin in febrile neutropenic patients. Arch Intern Med. 1985;145:1083-8.
30. O'Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 1989;87:605-13.
31. Brummett RE, Fox FE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797-800.
32. Feld R, Rachlis A, Tuffnell PG, Duncan I, Moran L, Pinfold P, et al. Empiric therapy for infections in patients with granulocytopenia: continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med. 1984;144:1005-10.
33. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 1987;107:900-9.
34. Johnston MP, Ramphal R. Beta-lactam-resistant Enterobacter bxbacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis. 1990;162:981-3.
35. Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer. 1972;29:1697-701.
36. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis. 1991;164:907-16.